Next Issue
Volume 3, June
Previous Issue
Volume 2, December
 
 

J. Pers. Med., Volume 3, Issue 1 (March 2013) – 4 articles , Pages 1-69

  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list.
  • You may sign up for e-mail alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.
Order results
Result details
Section
Select all
Export citation of selected articles as:
474 KiB  
Review
Personalized Medicine in Ophthalmology: From Pharmacogenetic Biomarkers to Therapeutic and Dosage Optimization
by Frank S. Ong, Jane Z. Kuo, Wei-Chi Wu, Ching-Yu Cheng, Wendell-Lamar B. Blackwell, Brian L. Taylor, Wayne W. Grody, Jerome I. Rotter, Chi-Chun Lai and Tien Y. Wong
J. Pers. Med. 2013, 3(1), 40-69; https://doi.org/10.3390/jpm3010040 - 05 Mar 2013
Cited by 18 | Viewed by 8204
Abstract
Rapid progress in genomics and nanotechnology continue to advance our approach to patient care, from diagnosis and prognosis, to targeting and personalization of therapeutics. However, the clinical application of molecular diagnostics in ophthalmology has been limited even though there have been demonstrations of [...] Read more.
Rapid progress in genomics and nanotechnology continue to advance our approach to patient care, from diagnosis and prognosis, to targeting and personalization of therapeutics. However, the clinical application of molecular diagnostics in ophthalmology has been limited even though there have been demonstrations of disease risk and pharmacogenetic associations. There is a high clinical need for therapeutic personalization and dosage optimization in ophthalmology and may be the focus of individualized medicine in this specialty. In several retinal conditions, such as age-related macular degeneration, diabetic macular edema, retinal vein occlusion and pre-threshold retinopathy of prematurity, anti-vascular endothelial growth factor therapeutics have resulted in enhanced outcomes. In glaucoma, recent advances in cytoskeletal agents and prostaglandin molecules that affect outflow and remodel the trabecular meshwork have demonstrated improved intraocular pressure control. Application of recent developments in nanoemulsion and polymeric micelle for targeted delivery and drug release are models of dosage optimization, increasing efficacy and improving outcomes in these major eye diseases. Full article
(This article belongs to the Special Issue Dosage Personalization in Modern Medicine)
363 KiB  
Article
Sensors: Views of Staff of a Disability Service Organization
by Gregor Wolbring and Verlyn Leopatra
J. Pers. Med. 2013, 3(1), 23-39; https://doi.org/10.3390/jpm3010023 - 22 Feb 2013
Cited by 20 | Viewed by 7012
Abstract
Sensors have become ubiquitous in their reach and scope of application. They are a technological cornerstone for various modes of health surveillance and participatory medicine—such as quantifying oneself; they are also employed to track people with certain as impairments perceived ability differences. This [...] Read more.
Sensors have become ubiquitous in their reach and scope of application. They are a technological cornerstone for various modes of health surveillance and participatory medicine—such as quantifying oneself; they are also employed to track people with certain as impairments perceived ability differences. This paper presents quantitative and qualitative data of an exploratory, non-generalizable study into the perceptions, attitudes and concerns of staff of a disability service organization, that mostly serve people with intellectual disabilities, towards the use of various types of sensor technologies that might be used by and with their clients. In addition, perspectives of various types of privacy issues linked to sensors, as well data regarding the concept of quantified self were obtained. Our results highlight the need to involve disabled people and their support networks in sensor and quantified-self discourses, in order to prevent undue disadvantages. Full article
310 KiB  
Opinion
Driving Forces Behind the Past and Future Emergence of Personalized Medicine
by Julius Alexander Steffen and Jan Simon Steffen
J. Pers. Med. 2013, 3(1), 14-22; https://doi.org/10.3390/jpm3010014 - 17 Jan 2013
Cited by 6 | Viewed by 6296
Abstract
Personalized medicine can be seen as a continuously developing approach to tailoring treatments according to the individual characteristics of a patient. In some way, medicine has always been personalized. During the last decade, however, scientific and technological progress have made truly personalized healthcare [...] Read more.
Personalized medicine can be seen as a continuously developing approach to tailoring treatments according to the individual characteristics of a patient. In some way, medicine has always been personalized. During the last decade, however, scientific and technological progress have made truly personalized healthcare increasingly become reality. Today’s personalized medicine involves targeted therapies and diagnostic tests. The development of targeted agents represents a major investment opportunity to pharmaceutical companies, which have been facing the need to diversify their business due to an increasingly challenging market place. By investing into the development of personalized therapies, pharmaceutical companies mitigate a major part of the risks posed by factors such as patent expiries or generic competition. Viewing upon personalized medicine from different perspectives points out the multi-causality of its emergence. Research efforts and business diversification have been two main driving forces; they do supplement each other, however, are not jointly exhaustive in explaining the emergence of this approach. Especially in the future, a number of further stakeholders will impact the evolution of personalized medicine. Full article
Show Figures

Figure 1

240 KiB  
Review
Structured Decision-Making: Using Personalized Medicine to Improve the Value of Cancer Care
by Bradford R. Hirsch and Amy P. Abernethy
J. Pers. Med. 2013, 3(1), 1-13; https://doi.org/10.3390/jpm3010001 - 27 Dec 2012
Cited by 14 | Viewed by 6795
Abstract
Cancer care is often inconsistently delivered with inadequate incorporation of patient values and objective evidence into decision-making. Utilization of time limited trials of care with predefined decision points that are based on iteratively updated best evidence, tools that inform providers about a patient’s [...] Read more.
Cancer care is often inconsistently delivered with inadequate incorporation of patient values and objective evidence into decision-making. Utilization of time limited trials of care with predefined decision points that are based on iteratively updated best evidence, tools that inform providers about a patient’s experience and values, and known information about a patient’s disease will allow superior matched care to be delivered. Personalized medicine does not merely refer to the incorporation of genetic information into clinical care, it involves utilization of the wide array of data points relevant to care, many of which are readily available at the bedside today. By pushing uptake of personalized matching available today, clinicians can better address the triple aim of improved health, lowers costs, and enhanced patient experience, and we can prepare the health care landscape for the iterative inclusion of progressively more sophisticated information as newer tests and information become available to support the personalized medicine paradigm. Full article
Show Figures

Figure 1

Previous Issue
Next Issue
Back to TopTop